Hormone therapy and in-hospital survival after myocardial infarction in postmenopausal women

Area of Science:

• Cardiovascular Medicine
• Endocrinology
• Public Health

Background:

• Postmenopausal hormone therapy (HRT) is commonly used for coronary heart disease prevention.
• The impact of HRT on myocardial infarction (MI) case fatality has not been previously investigated.
• This study examines HRT's role in post-MI survival among postmenopausal women.

Purpose of the Study:

• To evaluate hormone therapy (HRT) as a predictor of survival after myocardial infarction (MI).
• To assess the association between HRT use and mortality rates in postmenopausal women post-MI.

Main Methods:

• Analysis of 114,724 women aged 55+ with confirmed MI between April 1998 and January 2000.
• Data collected via chart review from 1674 hospitals in the National Registry of Myocardial Infarction-3.
• Comparison of mortality rates between HRT users (6.4%) and non-users, with adjustments for medical history, clinical factors, and treatment.

Main Results:

• Unadjusted mortality was significantly lower in HRT users (7.4%) compared to non-users (16.2%).
• After multivariable adjustment, HRT remained associated with improved survival post-MI (OR 0.65; 95% CI 0.59-0.72).
• This association was consistent across all age strata.

Conclusions:

• Postmenopausal hormone therapy (HRT) use appears to be associated with reduced mortality following myocardial infarction.
• Potential explanations include a therapeutic effect of HRT, selection bias, adherence bias, or a combination.
• Further research is needed to elucidate the mechanisms behind this observed association.